RE-induction and maintenance therapy with subcutaneous certolizumab pegial in patients with Crohn's disease following treatment failure: Precise 4 results

被引：0

作者：

Sandborn, William J.

Hanauer, Stephen B.

Rutgeerts, Paul J.

Colombel, Jean-frederic

Schreiber, Stefan

机构：

来源：

GASTROENTEROLOGY | 2007年 / 132卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：A505 / A505

页数：1

共 50 条

[1] Sustained Remission with No Dose Escalation after Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation: 1-Year Results from PRECiSE 4
Sandborn, William
Rubin, David
Sen, David
Feagan, Brian
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S439 - S439
[2] Long-term maintenance of remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation: 3-year results from the PRECiSE 4 study
Sandborn, W.
Schreiber, S.
Hanauer, S.
Colombel, J.
Bloomfield, R.
Lichtenstein, G.
[J]. INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S14 - S14
[3] Remission Rates in Crohn's Disease Patients Treated With a Re-Induction Regimen of Certolizumab Pegol After Experiencing Disease Exacerbation: 7 Year Results From the Precise 4 Study
Lee, Scott D.
Schreiber, Stefan
Schwartz, David A.
Burakoff, Robert
Binion, David G.
Kayhan, Cem
Kosutic, Gordana
Ambarkhane, Sumeet
Sen, David
Hasan, Iram
Spearman, Marshall
Sandborn, William
[J]. GASTROENTEROLOGY, 2015, 148 (04) : S261 - S261
[4] Re-induction with certolizumab pegol following disease exacerbation during maintenance therapy is effective to regain response and remission
Lichtenstein, Gary R.
Mitchev, Krassimir
D'Haens, Geert
[J]. GASTROENTEROLOGY, 2008, 134 (04) : A488 - A488
[5] Long-term Maintenance of Remission with No Dose Escalation Aft er Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation: 3-year Results from the PRECiSE 4 Study
Sandborn, William
Schreiber, Stefan
Hanauer, Stephen
Colombel, Jean-Frederick
Bloomfield, Ralph
Lichtenstein, Gary
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S448 - S448
[6] Incidence and Predictors of Clinical Response, Re-induction Dose, and Maintenance Dose Escalation with Certolizumab Pegol in Crohn's Disease
Stein, Adam C.
Rubin, David T.
Hanauer, Stephen B.
Cohen, Russell D.
[J]. INFLAMMATORY BOWEL DISEASES, 2014, 20 (10) : 1722 - 1728
[7] Efficacy of Certolizumab Pegol Induction and Maintenance Therapy in Patients With Crohn's Disease Not in Remission Following Active or Placebo Induction
Sandborn, William J.
Younes, Ziad H.
Pierre-Louis, Bosny
D'Haens, Geert R.
[J]. GASTROENTEROLOGY, 2012, 142 (05) : S565 - S565
[8] Long-term Maintenance of Remission with No Dose Escalation After Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation Who Were Naive to Anti-TNF Treatment: 4-Year Results from the PRECiSE 4 Study
Sandborn, William
Schreiber, Stefan
Hanauer, Stephen
Colombel, Jean-Frederic
Bloomfield, Ralph
Lichtenstein, Gary
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S418 - S418
[9] Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation who were naive to anti-TNF treatment: 4-year results from PRECiSE 4.
Sandborn, W.
Schreiber, S.
Hanauer, S.
Colombel, J.
Bloomfield, R.
Lichtenstein, G.
[J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S60 - S60
[10] Sustained Remission With No Dose Escalation After Re-Induction With Certolizumab Pegol in Patients With Crohn's Disease Exacerbation Who Were NaiVE to Anti-TNF Treatment: 5-Year Results From Precise 4
Sandborn, William J.
Schreiber, Stefan
Colombel, Jean-Frederic
Sen, David L.
Lichtenstein, Gary R.
[J]. GASTROENTEROLOGY, 2011, 140 (05) : S65 - S66

← 1 2 3 4 5 →